{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:45:10Z","timestamp":1782927910536,"version":"3.54.5"},"reference-count":14,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T00:00:00Z","timestamp":1161734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p> <jats:italic>Background:<\/jats:italic> Vitiligo is an acquired, pigmentary skin disorder which is disfiguring and difficult to treat. In an earlier open label study in adult patients with vitiligo, pimecrolimus cream 1% was reported to have similar efficacy as clobetasol propionate 0.05%. We performed a double\u2010blind, intrapatient comparison of pimecrolimus cream 1% with placebo cream.<\/jats:p><jats:p> <jats:italic>Patients and methods:<\/jats:italic> Twenty adult Caucasians with symmetrical vitiligo (predominantly on extremities, none in the face) were treated b.i.d. for 6 months left\/right with pimecrolimus\/vehicle (N = 10) or vehicle\/pimecrolimus (N = 10), respectively. Primary efficacy endpoint was the size of the target lesion at month 6 and secondary efficacy endpoint was re\u2010pigmentation.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Treatment with pimecrolimus cream 1% or vehicle resulted in no significant change in mean target lesion size. Modest repigmentation (1\u201325%) was noted with pimecrolimus at month 2 in 12 of 17 patients (vehicle: 9 of 17 patients). Afterwards, the number of patients who experienced an improvement of pigmentation steadily decreased (3 of 14 patients with pimecrolimus and 2 of 14 with placebo at month 6).Treatment was well tolerated.There were no treatment\u2010related adverse events, no induction of skin atrophy nor any other application site side effects.<\/jats:p><jats:p> <jats:italic>Conclusion:<\/jats:italic> In this group of adult patients with symmetrical vitiligo, treatment of body lesions (except face) with pimecrolimus cream 1% could not be shown to be effective.<\/jats:p>","DOI":"10.1111\/j.1610-0387.2006.06124.x","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T15:36:55Z","timestamp":1161790615000},"page":"942-946","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: Results of a randomized, double\u2010blind, vehicle\u2010controlled study"],"prefix":"10.1111","volume":"4","author":[{"given":"Markus","family":"Dawid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marge","family":"Veensalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Grassberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"839","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Ortonne JP","year":"2003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70194-X"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565040-00002"},{"key":"e_1_2_6_5_2","first-page":"88","article-title":"Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo","volume":"15","author":"Coskun B","year":"2005","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.5.581"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200405060-00013"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1492"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.4.407"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1984.01650410073019"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126500"},{"issue":"3","key":"e_1_2_6_12_2","first-page":"182 (P2\u201335)","article-title":"Pimecrolimus cream 1% is effective, well tolerated and safe in infants\/children with atopic eczema of the face (conference abstract)","volume":"17","author":"Barba JF","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.1.e2"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000073099"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.3.643"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2006.06124.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2006.06124.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:52:52Z","timestamp":1697046772000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2006.06124.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,25]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1111\/j.1610-0387.2006.06124.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2006.06124.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,25]]}}}